Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors Summary This Nature paper reports the discovery and preclinical validation of orally bioavailable, cell‑permeable macrocyclic peptides that block RxL‑mediated docking on cyclins…
